Combination hypoglycemic drugs: new opportunities for achieving diabetes control
The article addresses pathogenetical mechanisms of type 2 diabetes mellitus - insulin resistance and dysfunction of pancreatic islet beta cells. Recomendations on medical treatment of patients with type 2 diabetes are presented. Using the example of combination drug Glucovance (metformin + micronized glibenclamide) the benefits of combination hypoglycemic preparations are analyzed.